Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections

被引：397

作者：

Steenbergen, JN ^{[1
]}

Alder, J ^{[1
]}

Thorne, GM ^{[1
]}

Tally, FP ^{[1
]}

机构：

[1] Cubist Pharmaceut Inc, Lexington, MA 02421 USA

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2005年 / 55卷 / 03期

关键词：

MRSA; cSSSI; vancomycin;

D O I：

10.1093/jac/dkh546

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Infections caused by drug-resistant pathogens are on the rise. Daptomycin, a cyclic lipopeptide with activity against most Gram-positive pathogens, including vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus, is a newly US-FDA approved antimicrobial for complicated skin and skin structure infections (cSSSI). Daptomycin has a unique mechanism of action that results in destruction of the membrane potential. The rapid bactericidal activity of daptomycin makes it an attractive antibiotic for serious Gram-positive infections.

引用

收藏

页码：283 / 288

页数：6

相关论文

共 45 条

[11] Daptomycin dose-effect relationship against resistant gram-positive organisms [J].

Cha, R ;

Grucz, RG ;

Rybak, MJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (05) :1598-1603

[12] Influence of protein binding under controlled conditions on the bactericidal activity of daptomycin in an in vitro pharmacodynamic model [J].

Cha, R ;

Rybak, MJ .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (01) :259-262

[13] Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis [J].

Cottagnoud, P ;

Pfister, M ;

Acosta, F ;

Cottagnoud, M ;

Flatz, L ;

Kühn, F ;

Müller, HP ;

Stucki, A .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (10) :3928-3933

[14] Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001 [J].

Critchley, IA ;

Draghi, DC ;

Sahm, DF ;

Thornsberry, C ;

Jones, ME ;

Karlowsky, JA .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (03) :639-649

[15] Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus [J].

Cui, L ;

Ma, XX ;

Sato, K ;

Okuma, K ;

Tenover, FC ;

Mamizuka, EM ;

Gemmell, CG ;

Kim, MN ;

Ploy, MC ;

El Solh, N ;

Ferraz, V ;

Hiramatsu, K .

JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (01) :5-14

[16] Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model [J].

Dandekar, PK ;

Tessier, PR ;

Williams, P ;

Nightingale, CH ;

Nicolau, DP .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (03) :405-411

[17] Daptomycin in vitro susceptibility in European Gram-positive clinical isolates [J].

Fluit, AC ;

Schmitz, FJ ;

Verhoef, J ;

Milatovic, D .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 24 (01) :59-66

[18] In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants [J].

Fluit, AC ;

Schmitz, FJ ;

Verhoef, J ;

Milatovic, D .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (03) :1007-1011

[19] Epidemiology and susceptibility of 3,051 Staphylococcus aureus isolates from 25 university hospitals participating in the European SENTRY study [J].

Fluit, AC ;

Wielders, CLC ;

Verhoef, J ;

Schmitz, FJ .

JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (10) :3727-3732

[20] In vitro bactericidal activity of daptomycin against staphylococci [J].

Fuchs, PC ;

Barry, AL ;

Brown, SD .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 (03) :467-470

← 1 2 3 4 5 →